Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America
September 11, 2023Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …
CymaBay shares results from phase 3 RESPONSE trial for seladelpar
September 8, 2023Research and Development CymaBay, PBC, Pharmacy, clinical trial, seladelpar
CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …
Vaxart shares topline data from phase 2 study of norovirus vaccine candidate
September 8, 2023Research and Development Infections and infestations, Vaccine, Vaxart, norovirus
Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …
Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate
September 7, 2023Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …
BridgeBio Pharma shares positive feedback from FDA and EMA for phase 3 trial of infigratinib
September 7, 2023Research and Development BridgeBio Pharma, EMA, FDA, Musculo-skeletal disorder, achondroplasia, clinical trial
BridgeBio Pharma has announced positive feedback from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on …
Abbott to acquire Bigfoot Biomedical
September 6, 2023Business Services Abbott, Bigfoot Biomedical, Diabetes, acquisition, diabetes
Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …
Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase
September 6, 2023Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase
Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
September 5, 2023Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
FDA approves new ADHD and BED generics
September 1, 2023Medical Communications BED, FDA, Pharmacy, generic medicines
The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …
First patient dosed in phase 1 study for chronic hepatitis B treatment
August 31, 2023Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B
ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
Twist Bioscience and Ono Pharmaceutical enter agreement for discovery of novel antibodies
August 31, 2023Research and Development Immunology, Ono Pharmaceutical, Twist Bioscience, antibodies, autoimmune diseases
Twist Bioscience has announced that it has entered a drug discovery agreement with Ono Pharmaceutical for the discovery and development …
Novo Nordisk acquires Embark Biotech and its lead metabolic programme
August 31, 2023Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …
CN Bio introduces Dr Tomasz Kostrzewski as new chief scientific officer
August 31, 2023Business Services CN Bio, CSO, Dr Tomasz Kostrzewski, Microbiology
On 30August 2023, CN Bio announced the appointment of Dr Tomasz Kostrzewski as chief scientific officer (CSO) – a new …
Merck’s Keytruda approved by EC for gastric cancer
August 30, 2023Research and Development EC, Merck, Oncology, gastric cancer, keytruda
Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …
FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS
August 30, 2023Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …
EC approves Roche’s Evrysdi for babies under two months with SMA
August 30, 2023Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy
Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
